M Dadacaridou

Learn More
PURPOSE The purpose of this study was to assess the efficacy and toxicity of DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin), as third-line regimen in relapsed or refractory multiple myeloma (MM) patients. PATIENTS AND METHODS Twelve patients (11 men, 1 woman, aged 38-73 years, median 58) with relapsed or refractory MM received 28 cycles of(More)
  • 1